The Boston-based startup, which has now raised over $27 million in total capital, aims to address the significant care gaps within the U.S. healthcare system. While GI issues drive $136 billion in annual spending—surpassing the costs of diabetes and heart disease—nearly 70% of U.S. counties lack a single practicing gastroenterologist. Ayble’s platform attempts to bridge this divide by pairing patients with a specialized team of dietitians, behavioral health experts, and pharmacists, all supported by a massive proprietary GI dataset.

Founder and CEO Sam Jactel, who developed the company based on his personal experience with Inflammatory Bowel Disease, noted that the funding will allow the firm to treat patients holistically as they often manage overlapping autoimmune comorbidities. The company currently covers 80 million Americans through partnerships with major health plans and employers. This growth is backed by rigorous clinical validation, including 16 peer-reviewed studies and recognition from the Peterson Health Technology Institute. Kimmy Scotti, managing partner at Neon, cited this clinical evidence as a key factor in the firm's decision to lead the investment, emphasizing that Ayble’s model has proven effective at reducing high-cost medical utilization for enterprise partners.